Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis
详细信息 查看全文
- 作者：Yun-Xin Lua ; b ; 1 ; Huai-Qiang Jua ; 1 ; Feng Wanga ; b ; 1 ; Le-Zong Chena ; b ; Qi-Nian Wua ; b ; Hui Shenga ; Hai-Yu Moa ; Zhi-Zhong Pana ; c ; Dan Xiea ; Tie-Bang Kanga ; Gong Chena ; c ; Jing-Ping Yuna ; d ; Zhao-Lei Zenga ; Rui-Hua Xua ; b ; xurh@sysucc.org.cn" class="auth_mail" title="E-mail the corresponding author
- 关键词：Nafamostat mesilate ; Colorectal cancer ; Chemoresistance ; Nuclear factor kappa B ; Oxaliplatin
- 刊名：Cancer Letters
- 出版年：2016
- 出版时间：28 September 2016
- 年：2016
- 卷：380
- 期：1
- 页码：87-97
- 全文大小：3044 K
文摘
- •
Nafamostat mesilate inhibits NF-κB and Erk signaling in CRC.
- •
Nafamostat mesilate suppresses growth and metastasis of CRC.
- •
Oxaliplatin activates NF-κB and Erk signaling in CRC.
- •
Nafamostat mesilate and oxaliplatin demonstrate synergism in CRC.